



Practitioner's Docket No. 48170.00040/PC832

*(F2)*  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Frances Titus, et al.

Application No.: 10/806,915

Group No.: 1636

Filed: March 23, 2004

Examiner: Celine Qian

For: INTRACELLULAR DELIVERY OF OSTEOINDUCTIVE PROTEINS AND PEPTIDES

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
WITHIN THREE MONTHS OF FILING OR  
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. § 1.97(b))**

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

The Supplemental Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b).

Date: December 26, 2006

*V. Vasilyev*  
\_\_\_\_\_  
Vyacheslav Vasilyev  
Registration No. 58,154  
Fox Rothschild LLP  
997 Lenox Drive, Building 3  
Lawrenceville, NJ 08648  
609-844-3021  
Customer No. 29,880

---

**CERTIFICATION UNDER 37 C.F.R. § 1.8(a) and 1.10\***  
(When using Express Mail, the Express Mail label number is **mandatory**;  
*Express Mail certification is optional.*)

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**


deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: December 26, 2006


*Monique E. Harrell*  
\_\_\_\_\_  
Signature

Monique E. Harrell  
(type or print name of person certifying)

\* Only the date of filing (' 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under ' 1.8 continues to be taken into account in determining timeliness. See ' 1.703(f). Consider "Express Mail Post Office to Addressee" (' 1.10) or facsimile transmission (' 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 26, 2006      Signature: 

Monique E. Harrell

Docket No. 48170.00040/PC832  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of: :  
Frances Titus, et al. :  
Application No.: 10/806,915 : Group Art Unit: 1636  
Filed: March 23, 2004 : Examiner: Celine Qian  
For: INTRACELLULAR DELIVERY OF :  
OSTEOINDUCTIVE PROTEINS AND :  
PEPTIDES :  
X

**SUPPLEMENTAL INFORMATION**  
**DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In accordance with Applicants' duty of disclosure under 37 C.F.R. §1.56, and in accordance with 37 C.F.R. §§ 1.97-1.98, applicant submits the enclosed form PTO-1449 listing references for the Examiner's consideration for the above-listed patent application. This Supplemental Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and therefore no fee is supplied in accordance with 37 C.F.R. § 1.97(b)(3).

The non-patent references are being submitted herewith. The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that a search has been made, and shall not be construed to be an admission that the information cited in the statement is, or

Appl. No.: 10/806,915  
Filed: March 23, 2004

is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

If there are any questions, Applicant's attorney can be reached at the telephone number stated below.

Respectfully submitted,

FOX ROTHSCHILD, LLP  
997 Lenox Drive, Building 3  
Lawrenceville, NJ 08648

Dated: December 26, 2006

By: Vasiliyev  
Vyacheslav Vasiliyev  
Registration No. 58,154  
Attorney of Record  
(609) 844-3021 (Telephone)  
(609) 896-1469 (Facsimile)

<p>Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <small>(Use as many sheets as necessary)</small></p>		<p>Complete if Known</p> <p>Application Number 10/806,915  Filing Date March 23, 2004  First Named Inventor Frances Titus, et al.  Group Art Unit 1636  Examiner Name Celine Qian</p>
<p>Set 1 of 1</p>		Attorney Docket No: 48170.00040/PC832

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A	XIAOQING GUO, et al., "Transduction of Functionally Active TAT Fusion Proteins Into Cornea," <i>Experimental Eye Research</i> , Vol. 78, Pages 997-1005 (2004)	
	B	MICHELLE BECKER-HAPAK, et al., "TAT-Mediated Protein Transduction into Mammalian Cells," <i>Methods</i> , Vol. 24, Pages 247-256 (2001)	
	C	JEFFREY L. WRANA, "Crossing Smads," <i>Science's Stke</i> , Vol. 23, Pages 1-9 (2000)	
	D	KRISTIN A. WAITE, "From Developmental Disorder to Heritable Cancer: It's All in the BMP/TGF- $\beta$ Family," <i>Nature Reviews</i> , Vol. 4, Pages 763-773 (2003)	
	E	RIK DERYNCK, et al., "...Smad-dependent and Smad-independent Pathways in TGF- $\beta$ Family Signalling...," <i>Nature</i> , Vol. 425, Pages 577-584 (2003)	
	F	PATRICIA DUCY, et al., "The Family of Bone Morphogenetic Proteins," <i>Kidney International</i> , Vol. 57, Pages 2207-2214 (2000)	
	G	DOUGLAS HANAHAN, et al., "The Hallmarks of Cancer," <i>Cell</i> , Vol. 100, Pages 57-70 (2000)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached

LV1 450394v1 12/22/06